Humate-P

Background

  • Human Plasma-derived von Willebrand Factor
  • Contains both vWF and factor VIII

Indications

  • Hemophilia A (can also use factor VIII, FFP does not work well)
  • Von Willebrand disease that is unresponsive to DDAVP (can also use cryoprecipitate, FFP does not work well)

Administration

  • Type: blood products
  • Dosage Forms:
  • Routes of Administration:
  • Common Trade Names:

Adult Dosing

  • Von Willebrand disease
    • Major hemorrhage: loading dose 40-80 IU/kg IV
    • Minor hemorrhage: loading dose 40-50 IU/kg IV
  • Hemophilia A
    • Minor hemorrhage: Loading dose 15 IU/kg IV should achieve FVIII:C plasma level ~30% of normal
    • Moderate hemorrhage: Loading dose 25 IU/kg IV should achieve FVIII:C plasma level ~50% of normal
    • Life-threatening hemorrhage: 40-50 IU/kg IV initially, followed by 2-25 IU q8-12hr to maintain FVIII:C level at 80-100% of normal

Pediatric Dosing

  • Von Willebrand disease
    • Major hemorrhage: loading dose 40-80 IU/kg IV
    • Minor hemorrhage: loading dose 40-50 IU/kg IV

Special Populations

Renal Dosing

  • Not delineated

Hepatic Dosing

  • Not established

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

  • Respiratory distress
  • Anaphylaxis
  • Thromboembolic events
  • Hemolytic anemia (in massive doses)

Common

  • Pain
  • Pruritus
  • Rash, urticaria, edema
  • Fever/chills, flu-like illness, cough, pharyngitis, rhinitis
  • Paresthesia
  • Fatigue
  • Headache
  • Asthenia
  • Cellulitis
  • Chest pain
  • Dyspepsia, nausea/vomiting
  • Hepatitis

Pharmacology

  • Half-life: 10-11h
  • Metabolism:
  • Excretion:

Mechanism of Action

  • Human derived vWF

Comments

See Also

References